Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew McDonnell

Orthopaedic Surgery Somerset, NJ Medical Doctor

NPI 1770785883 CMS profile 584674

2 Worlds Fair Dr, Somerset, NJ 08873

Open in the dashboard

General payments

$62,007

137 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$637,533

4 holdings reported · through program year 2025

Through program year 2025, Matthew McDonnell of Somerset, NJ is reported in the CMS Open Payments database as having received $62,007 across 137 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $637,533 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,294 17
2024 General $16,623 11
2023 General $1,593 17
2022 General $7,055 21
2021 General $14,408 19
2020 General $5,337 16
2019 General $4,697 36
2025 Ownership $162,511 1
2024 Ownership $162,511 1
2023 Ownership $162,511 1
2022 Ownership $150,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew McDonnell
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Matthew McDonnell were reported at $12,294. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Matthew McDonnell Orthopaedic Surgery median Middle half National median
2019 $4,697 $644 $140–$2,844 $163
2020 $5,337 $312 $75–$1,860 $114
2021 $14,408 $520 $117–$2,495 $132
2022 $7,055 $598 $128–$2,731 $149
2023 $1,593 $461 $128–$2,264 $160
2024 $16,623 $497 $134–$2,475 $164
2025 $12,294 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Collagen Matrix, Inc $24,700 6 payments
  2. Stryker Corporation $9,201 12 payments
  3. Ethicon Inc. $8,213 5 payments
  4. Alphatec Spine, Inc $8,047 17 payments
  5. NuVasive, Inc. $5,805 54 payments
  6. Medical Device Business Services, Inc. $4,404 7 payments
  7. Baxter Healthcare $277 9 payments
  8. DePuy Synthes Sales Inc. $247 4 payments
  9. Stability Biologics, LLC $187 6 payments
  10. Royal Biologics $154 1 payment
  11. Other $772 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $48,540 16 payments
  2. Travel and Lodging $8,504 10 payments
  3. Food and Beverage $4,927 110 payments
  4. Entertainment $36 1 payment
Products named General payments · program years 2019–2025
  1. EVEREST SPINAL SYSTEM $8,902 6 payments
  2. CAPRI CORPECTOMY CAGE SYSTEM $8,000 1 payment
  3. MESA SPINAL SYSTEM $8,000 1 payment
  4. Other - Miscellaneous $6,429 7 payments
  5. EXPEDIUM $3,600 1 payment
  6. Velys $804 6 payments
  7. Invictus MIS $772 2 payments
  8. ACP $537 5 payments
  9. AttraX $360 16 payments
  10. Stimulan $151 1 payment
  11. Other $2,615 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

248

Median for Orthopedic Surgery: 203

Drug cost

$1,481

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cyclobenzaprine Hcl Generic 76 $523
Methylprednisolone Generic 44 $288
Cephalexin Generic 17 $250
Gabapentin Generic 47 $226
Meloxicam Generic 64 $195

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$217,205

Medicare's payments for the services billed

Medicare patients

363

Average age 75

Services billed

1,547

214 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 37%
Diabetes 35%
Depression 25%
Osteoporosis 25%
Chronic kidney disease 17%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record